China Pharma Holdings, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; comparisons are to FY2020. The company develops, manufactures and sells pharmaceuticals in China, principally prescription generic drugs, through its PRC subsidiary and distributor network. Its 2021 portfolio included 19 pharmaceutical products and healthcare and protective products.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $9.64 million | $10.87 million |
| Gross profit / margin | $0.35 million / 3.6% | $1.95 million / 18.0% |
| Operating loss | $2.86 million | $2.58 million |
| Net loss | $3.40 million | $2.87 million |
| Loss per share, basic and diluted | $0.07 | $0.07 |
| Cash used in operating activities | $0.25 million | $0.04 million |
| Cash used in investing activities | $0.44 million | $0.87 million |
| Cash provided by financing activities | $4.60 million | $0.62 million |
- Reported revenue fell about 11% year over year, primarily because FY2020 included approximately $1.73 million of one-time COVID-19 test-kit export revenue. Excluding those kits, domestic pharmaceutical revenue was $9.64 million in 2021 versus $9.13 million in 2020, an increase of about 6%.
- Gross margin contracted sharply as the company said key-product prices declined and raw-material and packaging costs increased; the prior-year test-kit transaction also had a relatively high margin. Selling expenses declined to $1.50 million from $2.22 million. R&D expense was $0.32 million, mainly for generic-drug consistency evaluations.
- Cash and cash equivalents were $4.86 million at year-end, up from $0.96 million. Current assets were $9.09 million and current liabilities $10.51 million, leaving a $1.42 million working-capital deficit. Net accounts receivable was $0.71 million and inventory $3.34 million.
- Net interest expense increased to $0.54 million from $0.29 million. The balance sheet reported $5.25 million of convertible note payable, $4.33 million of current lines of credit, and $2.78 million of borrowings from related parties. The company also reported $0.82 million of deferred tax liability.
Material changes and unusual items
- FY2021 net loss worsened by about $0.53 million. Despite lower revenue, costs of revenue rose to $9.29 million from $8.91 million, reducing gross profit from $1.95 million to $0.35 million.
- The company completed a $5.0 million financing in November 2021 through an unsecured convertible note with $5.25 million original principal and a 15-month maturity. It carries 5% interest compounded daily, permits monthly redemptions subject to limits, and may convert at 85% of the lowest VWAP in the preceding ten trading days. The filing calculates potential conversion into 11.98 million shares at December 31, 2021. In March 2022, a $100,000 redemption resulted in issuance of 321,233 shares.
- The company issued 1.76 million shares to its chairperson, CEO and interim CFO in 2021 in lieu of $1.18 million of compensation. It also received working-capital advances from the CEO, with $1.43 million owed at year-end; a director was owed $1.35 million under 1% loans.
- The company repaid the remaining construction term-loan principal during 2021. It obtained or renewed short-term credit facilities, including a $1.54 million Bank of China facility secured by its production facility and personally guaranteed by its CEO and chairperson.
Outlook, risks and controls
- Management gave no quantified revenue or earnings guidance. Its stated priorities include collecting receivables, using advance-payment sales where possible, progressing consistency evaluations, and exploring faster launch of nutrition products, online/offline sales, and CDMO services.
- Management expects operating losses to continue. The auditor’s report highlights substantial doubt about the company’s ability to continue as a going concern, citing recurring operating losses, net current liabilities and accumulated deficit. Management’s proposed remedies—including improved collections, nutrition-product launches and potential borrowing against fixed assets—were not sufficiently finalized or within its control to alleviate that doubt. The financial statements include no adjustments for a possible outcome.
- China’s centralized drug procurement and medical-insurance cost controls create significant pricing and margin pressure. Failure to pass required generic-drug consistency evaluations could restrict procurement eligibility. Other cited exposures include COVID-19 disruption, competition, distributor and customer concentration, raw-material supply, PRC regulation and currency controls, and restrictions on transfers of funds out of China.
- Management concluded internal control over financial reporting and disclosure controls were ineffective at year-end due to a material weakness: insufficient personnel knowledgeable in U.S. GAAP. Management described training and process-review remediation steps. The auditor did not attest to internal-control effectiveness.
- The company reported no legal proceedings believed likely to have a material adverse effect and no off-balance-sheet arrangements. It does not anticipate paying cash dividends.
Investor verification points
- Assess going-concern risk, cash runway and the company’s ability to fund operations without additional financing.
- Review the convertible note’s redemption and conversion terms, subsequent share issuance, and potential dilution; reconcile the note’s stated principal, carrying value and conversion disclosures.
- Verify receivable collectability and customer concentration: three customers represented 52.1%, 11.2% and 10.2% of year-end receivables. The filing’s aging table reports 96.48% of receivables as over 720 days old; confirm the underlying balances and presentation.
- Track gross-margin recovery, product pricing and raw-material costs, especially under centralized procurement.
- Monitor consistency-evaluation submissions and approvals, as well as remediation of the material weakness in financial reporting controls.
- Confirm refinancing or repayment of credit facilities falling due in 2022 and the availability of funds from PRC operations, given foreign-exchange and dividend-remittance restrictions.